Skip to main content
. Author manuscript; available in PMC: 2020 Dec 12.
Published in final edited form as: Antivir Ther. 2010;15(7):935–950. doi: 10.3851/IMP1667

Figure 8.

Figure 8.

Metabolic activation and antiviral activity of cyclic monophosphate prodrugs of modified adenosines

aFrom reference [57]. bEffective concentration of compound required to reduce HCV replication by 50% (EC50). cConcentration of inhibitor reducing cell viability by 50% (CC50). dFrom reference [48]. eParent nucleoside (Nuc). Oi-Pr, O-isopropyl; t-Bu, tert-butyl.